New treatments for atrial fibrillation using engineered proteins
Peptibodies As Novel Therapies in Atrial Fibrillation
['FUNDING_R01'] · UNIVERSITY OF SOUTH FLORIDA · NIH-11003662
This study is exploring new treatments for atrial fibrillation (AF) by using special proteins called peptibodies that could help restore a normal heart rhythm more effectively than current options, and it’s designed for people who are looking for better ways to manage their AF.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF SOUTH FLORIDA (nih funded) |
| Locations | 1 site (TAMPA, UNITED STATES) |
| Trial ID | NIH-11003662 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative therapies for atrial fibrillation (AF), a common heart rhythm disorder that is difficult to treat. The approach involves creating peptibodies, which are engineered proteins that combine the therapeutic effects of specific peptides with the stability of antibodies. By blocking a specific ion channel that contributes to AF, these peptibodies aim to restore normal heart rhythm more effectively than current treatments. The research will involve testing these new therapies in preclinical models to assess their safety and efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with persistent atrial fibrillation who have not responded well to existing antiarrhythmic medications.
Not a fit: Patients with atrial fibrillation that is not persistent or those who have contraindications to new therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from persistent atrial fibrillation.
How similar studies have performed: Previous research has shown promise in using similar engineered proteins for other therapeutic applications, indicating potential for success in this novel approach.
Where this research is happening
TAMPA, UNITED STATES
- UNIVERSITY OF SOUTH FLORIDA — TAMPA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NOUJAIM, SAMI FOUAD — UNIVERSITY OF SOUTH FLORIDA
- Study coordinator: NOUJAIM, SAMI FOUAD
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.